GSK (LSE: GSK) shares was a no brainer purchase. Sadly, that was a very long time in the past. They’ve provided slim pickings for the final decade. Really, make that two.
In August 2006, the GSK share value traded at round 1,500p. Immediately, it’s 1,815p. That’s a rise of simply 21% over 20 years. Traders have gotten dividends on prime, however they haven’t been good both. What’s gone mistaken?
The quick reply is that the prescription drugs large’s spent years struggling to persuade buyers it has the medicine to ship significant development.
Why’s this FTSE 100 inventory struggling?
There have been pipeline disappointments, patent expiries and costly makes an attempt to construct a brand new era of medicines. R&D spending has risen sharply, reaching £6.57bn final 12 months. That funding’s mandatory, however shareholders have paid the worth.
The board froze the dividend at 80p per share in 2015 and held it there for seven straight years. Then got here the Haleon demerger in 2022 and the payout fell to 57.75p, earlier than recovering to 66p final 12 months.
General efficiency has been patch too, as full-year earnings for the final 5 years present:
- 2025 – £7.93bn
- 2024 – £6.01bn
- 2023 – £6.75bn
- 2022 – £6.73bn
- 2021 – £6.20bn
2024 was hit by multi-billion pound Zantac settlement provisions, though robust development in Specialty Medicines and Vaccines boosted the 2025 quantity.
Emma Walmsley led GSK for nearly 9 years however when her departure was introduced in September 2025, the shares jumped amid hopes a brand new boss might lastly unlock GSK’s potential.
The shares are up 30% over one 12 months however now they’re falling once more, down 15% over six months. So anybody who had £6,000 in GSK shares then would have simply £5,100 right now, ignoring dividends.
Q2 outcomes (28 July) recommend new boss Luke Miels has his work minimize out. Whereas core working earnings rose 7% to £2.8bn, whole working revenue plunged 75%, largely due to a £1.3bn impairment linked primarily to a failed drug growth.
As soon as once more, GSK must replenish the pipeline and cope with looming patent expiries. But it’s not all gloom. 2026 gross sales and core-operating revenue are anticipated to land on the higher finish of their respective 2026 steering ranges of three%-5% and seven%-9%. Miels is concentrating on greater than £40bn of annual gross sales by 2031.
Is the inventory good worth?
I consider in shopping for shares for the long run. However 20 years is an awfully very long time to kick your heels. Immediately, GSK shares commerce on a modest price-to-earnings ratio of about 10.8. That appears low-cost however I gained’t get carried away. I purchased them on a P/E of eight, they usually haven’t come via for me. The trailing dividend yield is 3.64%.
I don’t have another healthcare publicity so I’m hanging on for diversification. But if I didn’t personal GSK shares, I wouldn’t rush to purchase them. So I gained’t stick my neck out and say they’re price contemplating right now. I can see much more thrilling dividend and development shares on the FTSE 100.
Do you have to make investments £5,000 in GSK proper now?
When investing knowledgeable Mark Rogers and his workforce have a inventory tip, it may pay to pay attention. In any case, the flagship Twelfth Magpie Share Advisor publication he has run for almost a decade has offered 1000’s of paying members with prime inventory suggestions from the UK and US markets.
And proper now, Mark thinks there are 6 standout shares that buyers ought to take into account shopping for. Wish to see if GSK made the listing?
Harvey Jones owns shares in GSK.
